Your browser doesn't support javascript.
loading
Factors Associated with COVID-19 Vaccine Booster Hesitancy: A Retrospective Cohort Study, Fukushima Vaccination Community Survey.
Yoshida, Makoto; Kobashi, Yurie; Kawamura, Takeshi; Shimazu, Yuzo; Nishikawa, Yoshitaka; Omata, Fumiya; Zhao, Tianchen; Yamamoto, Chika; Kaneko, Yudai; Nakayama, Aya; Takita, Morihito; Ito, Naomi; Kawashima, Moe; Sugiura, Sota; Shibuya, Kenji; Iwami, Shingo; Kim, Kwangsu; Iwanami, Shoya; Kodama, Tatsuhiko; Tsubokura, Masaharu.
Afiliação
  • Yoshida M; Faculty of Medicine, Teikyo University School of Medicine, Itabashi Campus, Tokyo 173-8605, Japan.
  • Kobashi Y; Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima 960-1247, Japan.
  • Kawamura T; Department of General Internal Medicine, Hirata Central Hospital, Fukushima 963-8202, Japan.
  • Shimazu Y; Proteomics Laboratory, Isotope Science Center, The University of Tokyo, Tokyo 113-0032, Japan.
  • Nishikawa Y; Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo 153-8904, Japan.
  • Omata F; Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima 960-1247, Japan.
  • Zhao T; Department of General Internal Medicine, Hirata Central Hospital, Fukushima 963-8202, Japan.
  • Yamamoto C; Department of General Internal Medicine, Hirata Central Hospital, Fukushima 963-8202, Japan.
  • Kaneko Y; Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima 960-1247, Japan.
  • Nakayama A; Japan Red Cross Society Fukushima Hospital, Fukushima 960-8530, Japan.
  • Takita M; Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo 153-8904, Japan.
  • Ito N; Medical & Biological Laboratories Co., Ltd., Tokyo 105-0012, Japan.
  • Kawashima M; Proteomics Laboratory, Isotope Science Center, The University of Tokyo, Tokyo 113-0032, Japan.
  • Sugiura S; Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima 960-1247, Japan.
  • Shibuya K; Medical Governance Research Institute, Tokyo 108-0074, Japan.
  • Iwami S; Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima 960-1247, Japan.
  • Kim K; Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima 960-1247, Japan.
  • Iwanami S; Medical Governance Research Institute, Tokyo 108-0074, Japan.
  • Kodama T; Soma Medical Center of Vaccination for COVID-19, Fukushima 976-8601, Japan.
  • Tsubokura M; Tokyo Foundation for Policy Research, Tokyo 106-6234, Japan.
Vaccines (Basel) ; 10(4)2022 Mar 26.
Article em En | MEDLINE | ID: mdl-35455264
This was a retrospective cohort study, which aimed to investigate the factors associated with hesitancy to receive a third dose of a coronavirus disease 2019 (COVID-19) vaccine. A paper-based questionnaire survey was administered to all participants. This study included participants who provided answers in the questionnaire about whether they had an intent to receive a third dose of a vaccine. Data on sex, age, area of residence, adverse reactions after the second vaccination, whether the third vaccination was desired, and reasons to accept or hesitate over the booster vaccination were retrieved. Among the 2439 participants, with a mean (±SD) age of 52.6 ± 18.9 years, and a median IgG-S antibody titer of 324.9 (AU/mL), 97.9% of participants indicated their intent to accept a third vaccination dose. The logistic regression revealed that participants of a younger age (OR = 0.98; 95% CI: 0.96-1.00) and with a higher antibody level (OR = 2.52; 95% CI: 1.27-4.99) were positively associated with hesitancy over the third vaccine. The efficacy of the COVID-19 vaccine and concerns about adverse reactions had a significant impact on behavior regarding the third vaccination. A rapid increase in the booster dose rate is needed to control the pandemic, and specific approaches should be taken with these groups that are likely to hesitate over the third vaccine, subsequently increasing booster contact rate.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article